Telbivudine: an effective anti-HBV drug for chronic hepatitis B patients with early on-treatment responses

Bibliography

• Blumberg BS, Alter JH, Visnich S. A ‘new’ antigen in leukemia sera. JAMA 1965;191:541-5
   PubMed Web of Science ®Google Scholar
• Bayer ME, Blumberg BS, Werner B. Particles associated with Australia antigen in the sera of patients with leukemia, Down's syndrome and hepatitis. Nature 1968;218:1057-9
   PubMed Web of Science ®Google Scholar
• Summers J, O'Connell A, Millman I. Genome of hepatitis B virus: restriction enzyme cleavage and structure of DNA extract from Dane particles. Proc Natl Acad Sci USA 1975;72:4597-601
   PubMed Web of Science ®Google Scholar
• Blumberg BS, Gerstley BJS, Hungerford DA, A serum antigen (Australia antigen) in Down's syndrome, leukemia and hepatitis. Ann Intern Med 1967;66:924-31
   PubMed Web of Science ®Google Scholar
• Hann HL, Kim CY, London WT, Hepatitis B virus and primary hepatocellular carcinoma: family studies in Korea. Int J Cancer 1982;30:47-51
   PubMed Web of Science ®Google Scholar
• Blumberg BS, Millman I. Vaccine against viral hepatitis and process. US3636191; 1972
   Google Scholar
• Standring DN, Bridges EG, Placidi L, Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother 2001;12(Suppl 1):119-29
   PubMedGoogle Scholar
• Golitsina N, Danehy F, Fellows R, Telbivudine phosphorylation by three enzymes: Implications for anti-hepatitis B virus activity in vitro and in the clinic [abstract 1000]. Hepatology 2006;44(Suppl 1):561A
   PubMedGoogle Scholar
• Hernandez-Santiago B, Placidi L, Cretton-Scott E, Pharmacology of beta-L-thymidine and beta-L-2'-deoxycytidine in Hep G2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus. Antimicrob Agents chemother 2002;46:1728-33
   PubMed Web of Science ®Google Scholar
• Seifer M, Patty A, Dukhan D, Telbivudine (LdT) preferentailly inhibits second (+) strand HBV DNA synthesis [abstract 412]. J Hepatol 2005;42(Suppl 2):151
   Google Scholar
• Semizarov D, Arzumanov A, Dyatkina N, Stereoisomers of deoxynucleoside 5´-triphosphates as substrates for template-dependent and-independent DNA polymerase. J Biol Chem 1997;272:9556-60
   PubMed Web of Science ®Google Scholar
• Shafritz DA, Shouval D, Sherman HI, Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem specimens. N Engl J Med 1981;305:1067-76
   PubMed Web of Science ®Google Scholar
• Newhold JE, Xin H, Tencza M, The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol 1995;69:3350-7
   PubMedGoogle Scholar
• Tuttleman JS, Porcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 1986;47:451-60
   PubMed Web of Science ®Google Scholar
• Wolsters L, Hansen B, Niesters H, Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol 2002;37:137-44
   PubMedGoogle Scholar
• Bryant ML, Bridges EG, Placidi L, Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother 2001;45:229-35
   PubMed Web of Science ®Google Scholar
• Lai CL, Gane E, Liaw YF, Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-88
   PubMed Web of Science ®Google Scholar
• Liaw YF, Gane E, Leung N, 2–year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486-95
   PubMed Web of Science ®Google Scholar
• Hou J, Yin YK, Xu D, Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B. Results at 1 year of a randomized, double-blind trial. Hepatology 2008;47:447-54
   PubMed Web of Science ®Google Scholar
• Chan HL, Heathcote EJ, Marcellin P, Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007;147:745-54
   PubMed Web of Science ®Google Scholar
• Wang Y, Jia J, Hou J, A phase III comparative trial of telbivudine vs. lamivudine in Chinese patients with chronic hepatitis B: two year results. Gastroenterology 2007;132(4 Suppl 1):A-763
   PubMedGoogle Scholar
• Jia J-D, Gane E, Wang Y-M, Prolonged efficacy and safety of 4 years continuous telbivudine treatment in chronic hepatitis B (CHB) patients from GLOBE and 015 studies. Hepatol Int 2010;4:2-93
   Google Scholar
• Ren H, Wang Y-M, Thongsawat S, Telbivudine induced HBeAg seroconversion in chronic hepatitis B (CHB) patients is durable during 2 years off-treatment follow-up. Hepatol Int 2010;4:94-345
   Google Scholar
• Liaw Y-F. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int 2009;3:425-33
   PubMed Web of Science ®Google Scholar
• Shi KQ, Zhang DZ, Guo SH, Short-term results of telbivudine versus Entecavir treatments in HBeAg-positive chronic hepatitis B patients in china (in Chinese). Zhonghua Gan Zang Bing Za Zhi 2008;16:641-5
   PubMedGoogle Scholar
• Locarnini S, Hatzakis A, Heathcote J, Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004;9:679-93
   PubMed Web of Science ®Google Scholar
• Heathcote EJ, Gane E, Lai CL, Salvage therapy with adefovir for virologic breakthrough in telbivudine-treated patients from the GLOBE study. Gastroenterology 2007;132(Suppl 1):A765
   Google Scholar
• Tipples GA, Ma MM, Fischer KP, Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996;24:714-17
   PubMed Web of Science ®Google Scholar
• Seifer M, Patty A, Serra L, Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitor adefovir and tenofovir. Antivir Res 2009;8:147-55
   Google Scholar
• Standring DN, Patty A, Chapron C, Resistance determination in patients experiencing virologic breakthrough following telbivudine or lamivudine therapy in the International GLOBE trial [absrtact 1781]. Gastroenterology 2007;132(Suppl 2):A766
   Google Scholar
• Zeuzem S, Gane E, Liaw YF, Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009;51:11-20
   PubMed Web of Science ®Google Scholar
• Zhang X, Rui J. Preliminary observation on myopathy occurring with telbivudine alone and telbivudine plus adefovir or interferon. Adverse Drug React J 2008. DOI CNKI:SUN:YWBL.0.2008-03-013
   Google Scholar